Retroviral Integration Target Site Selection

HIV-1 Integrase: Mechanism and Inhibitor Design

Volumn , Issue , 2011, Pages 51-65

  Ciuffi, Angela ^a   Bushman, Frederic ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chromatin accessibility model; Retroviral integration target site selection; Retroviral integration, gene therapy

Indexed keywords

EID: 84886205653     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118015377.ch5     Document Type: Chapter

References (171)

1. Jordan, A.; Defechereux, P.; Verdin, E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 2001, 20, 1726-1738
2. Jordan, A.; Bisgrove, D.; Verdin, E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 2003, 22, 1868-1877
3. Lewinski, M. K.; Bisgrove, D.; Shinn, P.; Chen, H.; Hoffmann, C.; Hannenhalli, S.; Verdin, E.; Berry, C. C.; Ecker, J. R.; Bushman, F. D. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J. Virol. 2005, 79, 6610-6619
4. Coffin, J. M.; Hughes, S.; Varmus, H. E. Retroviruses. Cold SpringHarborLaboratoryPress,ColdSpringHarbor,NY, 1997
5. Farnet, C.M.; Haseltine,W. A. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J. Virol. 1991, 65, 1910-1915
6. Farnet, C. M.; Bushman, F. D. HIV-1 cDNA integration: Requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell 1997, 88, 483-492
7. Miller, M. D.; Farnet, C. M.; Bushman, F. D. Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition. J. Virol. 1997, 71, 5382-5390
8. Carteau, S.; Batson, S. C.; Poljak, L.; Mouscadet, J. F.; de Rocquigny, H.; Darlix, J. L.; Roques, B. P.; Kas, E.; Auclair, C. Human immunodeficiency virus type 1 nucleocapsid protein specifically stimulates Mg2{thorn} -dependent DNA integration in vitro. J. Virol. 1997, 71, 6225-6229
9. Chen, H.; Engelman, A. The barrier-to-autointegration protein is a host factor for HIV type 1 integration. Proc. Natl. Acad. Sci. USA 1998, 95, 15270-15274
10. Li, L.; Farnet, C. M.; Anderson, W. F.; Bushman, F. D. Modulation of activity of Moloney murine leukemia virus preintegration complexes by host factors in vitro. J. Virol. 1998, 72, 2125-2131
11. Carteau, S.; Gorelick, R. J.; Bushman, F. D. Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: Stimulation by the viral nucleocapsid protein. J. Virol. 1999, 73, 6670-6679
12. Bushman, F. D. Host proteins in retroviral cDNA integration. Adv. Virus Res. 1999, 52, 301-317
13. Hindmarsh, P.; Leis, J. Retroviral DNA integration. Microbiol. Mol. Biol. Rev. 1999, 63, 836-843
14. Li, L.; Yoder, K.; Hansen, M. S.; Olvera, J.; Miller, M. D.; Bushman, F. D. Retroviral cDNA integration: Stimulation by HMG I family proteins. J. Virol. 2000, 74, 10965-10974
15. Harris, D.; Engelman, A. Both the structure and DNA binding function of the barrier-to-autointegration factor contribute to reconstitution of HIV type 1 integration in vitro. J. Biol. Chem. 2000, 275, 39671-39677
16. Bushman, F. D. Integration site selection by lentiviruses: Biology and possible control. Curr. Top. Microbiol. Immunol. 2002, 261, 165-177
17. Gao, K.; Gorelick, R. J.; Johnson, D. G.; Bushman, F. Cofactors for human immunodeficiency virus type 1 cDNA integration in vitro. J. Virol. 2003, 77, 1598-1603
18. Cherepanov, P.; Maertens, G.; Proost, P.; Devreese, B.; Van Beeumen, J.; Engelborghs, Y.; De Clercq, E.; Debyser, Z. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 2003, 278, 372-381
19. Engelman, A. The roles of cellular factors in retroviral integration. Curr. Top. Microbiol. Immunol. 2003, 281, 209-238
20. Cereseto, A.; Giacca, M. Integration site selection by retroviruses. AIDS Rev. 2004, 6, 13-21
21. Turlure, F.; Devroe, E.; Silver, P. A.; Engelman, A. Human cell proteins and human immunodeficiency virus DNA integration. Front. Biosci. 2004, 9, 3187-3208
22. Bushman, F.; Lewinski, M.; Ciuffi, A.; Barr, S.; Leipzig, J.; Hannenhalli, S.; Hoffmann, C. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 2005. 3, 848-858
23. Van Maele, B.; Debyser, Z. HIV-1 integration: An interplay between HIV-1 integrase, cellular and viral proteins. AIDS Rev. 2005, 7, 26-43
24. Vandegraaff, N.; Devroe, E.; Turlure, F.; Silver, P. A.; Engelman, A. Biochemical and genetic analyses of integraseinteracting proteins lens epithelium-derived growth factor (LEDGF)/p75 and hepatoma-derived growth factor related protein 2 (HRP2) in preintegration complex function and HIV-1 replication. Virology 2006, 346, 415-426
25. Ciuffi, A.;Bushman,F.D. RetroviralDNAintegration:HIVand the role of LEDGF/p75. Trends Genet. 2006, 22, 388-395
26. Van Maele, B.; Busschots, K.; Vandekerckhove, L.; Christ, F.; Debyser, Z. Cellular co-factors of HIV-1 integration. Trends Biochem. Sci. 2006, 31, 98-105
27. Goff, S. P. Host factors exploited by retroviruses. Nat. Rev. Microbiol. 2007, 5, 253-263
28. Al-Mawsawi, L. Q.; Neamati, N. Blocking interactions between HIV-1 integrase and cellular cofactors: An emerging anti-retroviral strategy. Trends Pharmacol. Sci. 2007, 28, 526-535
29. Engelman, A.; Mizuuchi, K.; Craigie, R. HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991, 67, 1211-1221
30. Yoder, K. E.; Bushman, F. D. Repair of gaps in retroviral DNA integration intermediates. J. Virol. 2000, 74, 11191-11200
31. Bushman, F. D. Lateral DNA Transfer: Mechanisms and Consequences. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001
32. Bushman, F. D.; Fujiwara, T.; Craigie, R. Retroviral DNA integration directed by HIV integration protein in vitro. Science 1990, 249, 1555-1558
33. Craigie, R.; Fujiwara, T.; Bushman, F. The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro. Cell 1990, 62, 829-837
34. Katz, R. A.; Merkel, G.; Kulkosky, J.; Leis, J.; Skalka, A. M. The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro. Cell 1990, 63, 87-95
35. Bushman, F. D.; Craigie, R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: Specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. USA 1991, 88, 1339-1343
36. Katzman, M.; Sudol, M. In vitro activities of purified visna virus integrase. J. Virol. 1994, 68, 3558-3569
37. Asante-Appiah, E.; Skalka, A. M. Molecular mechanisms in retrovirus DNA integration. Antiviral Res. 1997, 36, 139-156
38. Pryciak, P. M.; Muller, H. P.; Varmus, H. E. Simian virus 40 minichromosomes as targets for retroviral integration in vivo. Proc. Natl. Acad. Sci. USA 1992, 89, 9237-9241
39. Pryciak, P. M.; Sil, A.; Varmus, H. E. Retroviral integration into minichromosomes in vitro. EMBO J 1992, 11, 291-303
40. Bushman, F. D.; Craigie, R. Sequence requirements for integration of Moloney murine leukemia virus DNA in vitro. J. Virol. 1990, 64, 5645-5648
41. Pryciak, P. M.; Varmus, H. E. Nucleosomes, DNA-binding proteins, and DNA sequence modulate retroviral integration target site selection. Cell 1992, 69, 769-780
42. Leavitt, A. D.; Rose, R. B.; Varmus, H. E. Both substrate and target oligonucleotide sequences affect in vitro integration mediated by human immunodeficiency virus type 1 integrase protein produced in Saccharomyces cerevisiae. J. Virol. 1992, 66, 2359-2368
43. Stevens, S.W.; Griffith, J. D. Sequence analysis of the human DNA flanking sites of human immunodeficiency virus type 1 integration. J. Virol. 1996, 70, 6459-6462
44. Bor, Y. C.; Miller,M. D.; Bushman, F. D.; Orgel, L. E. Targetsequence preferences of HIV-1 integration complexes in vitro. Virology 1996, 222, 283-288
45. Carteau, S.; Hoffmann, C.; Bushman, F. Chromosome structure and human immunodeficiency virus type 1 cDNA integration: Centromeric alphoid repeats are a disfavored target. J. Virol. 1998, 72, 4005-4014
46. Holman, A. G.; Coffin, J. M. Symmetrical base preferences surrounding HIV-1, avian sarcoma/leukosis virus, and murine leukemia virus integration sites. Proc. Natl. Acad. Sci. USA 2005, 102, 6103-6107
47. Wu, X.; Li, Y.; Crise, B.; Burgess, S. M.; Munroe, D. J. Weak palindromic consensus sequences are a common feature found at the integration target sites of many retroviruses. J. Virol. 2005, 79, 5211-5214
48. Berry, C.; Hannenhalli, S.; Leipzig, J.; Bushman, F. D. Selection of target sites for mobile DNA integration in the human genome. PLoS Comput. Biol. 2006. 2, e157
49. Pruss, D.; Bushman, F. D.; Wolffe, A. P. Human immunodeficiency virus integrase directs integration to sites of severe DNA distortion within the nucleosome core. Proc. Natl. Acad. Sci. USA 1994, 91, 5913-5917
50. Pruss, D.; Reeves, R.; Bushman, F. D.; Wolffe, A. P. The influence of DNA and nucleosome structure on integration events directed by HIV integrase. J. Biol. Chem. 1994, 269, 25031-25041
51. Muller,H. P.;Varmus, H. E.DNAbending creates favored sites for retroviral integration: An explanation for preferred insertion sites in nucleosomes. EMBO J 1994, 13, 4704-4714
52. Chow, S. A.; Brown, P. O. Substrate features important for recognition and catalysis by human immunodeficiency virus type 1 integrase identified by using novel DNA substrates. J. Virol. 1994, 68, 3896-3907
53. Bor, Y. C.; Bushman, F. D.; Orgel, L. E. In vitro integration of human immunodeficiency virus type 1 cDNA into targets containing protein-induced bends. Proc. Natl. Acad. Sci. USA 1995, 92, 10334-10338
54. Taganov, K. D.; Cuesta, I.; Daniel, R.; Cirillo, L. A.; Katz, R. A.; Zaret, K. S.; Skalka, A. M. Integrase-specific enhancement and suppression of retroviral DNA integration by compacted chromatin structure in vitro. J. Virol. 2004, 78, 5848-5855
55. Bushman, F. D. Tethering human immunodeficiency virus 1 integrase to a DNA site directs integration to nearby sequences. Proc. Natl. Acad. Sci. USA 1994, 91, 9233-9237
56. Bushman, F. Targeting retroviral integration. Science 1995, 267, 1443-1444
57. Miller, M. D.; Bor, Y. C.; Bushman, F. Target DNA capture by HIV-1 integration complexes. Curr. Biol. 1995, 5, 1047-1056
58. Goulaouic, H.; Chow, S. A. Directed integration of viral DNA mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein. J. Virol. 1996, 70, 37-46
59. Katz, R. A.; Merkel, G.; Skalka, A. M. Targeting of retroviral integrase by fusion to a heterologous DNA binding domain: In vitro activities and incorporation of a fusion protein into viral particles. Virology 1996, 217, 178-190
60. Bushman, F. D.; Miller, M. D. Tethering human immunodeficiency virus type 1 preintegration complexes to target DNA promotes integration at nearby sites. J. Virol. 1997, 71, 458-464
61. Holmes-Son, M. L.; Chow, S. A. Integrase-lexA fusion proteins incorporated into human immunodeficiency virus type 1 that contains a catalytically inactive integrase gene are functional to mediate integration. J. Virol. 2000, 74, 11548-11556
62. Holmes-Son, M. L.; Appa, R. S.; Chow, S. A. Molecular genetics and target site specificity of retroviral integration. Adv. Genet. 2001, 43, 33-69
63. Holmes-Son, M. L.; Chow, S. A. Correct integration mediated by integrase-LexA fusion proteins incorporated into HIV-1. Mol. Ther. 2002, 5, 360-370
64. Tan,W.; Zhu, K.; Segal, D. J.; Barbas, C. F., 3rd; Chow, S. A. Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J. Virol. 2004, 78, 1301-1313
65. Tan, W.; Dong, Z.; Wilkinson, T. A.; Barbas, C. F., 3rd; Chow, S. A. Human immunodeficiency virus type 1 incorporated with fusion proteins consisting of integrase and the designed polydactyl zinc finger protein E2C can bias integration of viral DNA into a predetermined chromosomal region in human cells. J. Virol. 2006, 80, 1939-1948
66. Ciuffi, A.; Diamond, T. L.; Hwang, Y.; Marshall, H. M.; Bushman, F. D. Modulating target site selection during human immunodeficiency virus DNA integration in vitro with an engineered tethering factor. Hum. Gene. Ther. 2006, 17, 960-967
67. Venter, J. C.; Adams, M. D.; Myers, E. W.; Li, P. W.; Mural, R. J.; et al. The sequence of the human genome. Science 2001, 291, 1304-1351
68. Lander, E. S.; Linton, L. M.; Birren, B.; Nusbaum, C.; Zody, M. C.; et al. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860-921
69. McPherson, J. D.; Marra, M.; Hillier, L.; Waterston, R. H.; Chinwalla, A.; et al. A physical map of the human genome. Nature 2001, 409, 934-941
70. Waterston, R. H.; Lindblad-Toh, K.; Birney, E.; Rogers, J.; Abril, J. F.; et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002, 420, 520-562
71. Consortium, I. C. G. S. Sequence and comparative analysis of the chicken genome provide unique perspectives on vertebrate evolution. Nature 2004, 432, 695-716
72. Consortium, T. C. S. a. A. Initial sequence of the chimpanzee genome and comparison with the human genome. Nature 2005, 437, 69-87
73. Lindblad-Toh, K.; Wade, C. M.; Mikkelsen, T. S.; Karlsson, E. K.; Jaffe, D. B.; et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005, 438, 803-819
74. Schroder, A. R.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J. R.; Bushman, F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002, 110, 521-529
75. Wu, X.; Li, Y.; Crise, B.; Burgess, S. M. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300, 1749-1751
76. Mitchell, R. S.; Beitzel, B. F.; Schroder, A. R.; Shinn, P.; Chen, H.; Berry, C. C.; Ecker, J. R.; Bushman, F. D. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004, 2, E234
77. Hematti, P.; Hong, B. K.; Ferguson, C.; Adler, R.; Hanawa, H.; Sellers, S.; Holt, I. E.; Eckfeldt, C. E.; Sharma, Y.; Schmidt, M.; von Kalle, C.; Persons, D. A.; Billings, E. M.; Verfaillie, C. M.; Nienhuis, A. W.; Wolfsberg, T. G.; Dunbar, C. E.; Calmels, B. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2004, 2, e423
78. Narezkina, A.; Taganov, K. D.; Litwin, S.; Stoyanova, R.; Hayashi, J.; Seeger, C.; Skalka, A. M.; Katz, R. A. Genomewide analyses of avian sarcoma virus integration sites. J. Virol. 2004, 78, 11656-11663
79. Ciuffi, A.; Llano, M.; Poeschla, E.; Hoffmann, C.; Leipzig, J.; Shinn, P.; Ecker, J. R.; Bushman, F. A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 2005. 11, 1287-1289
80. Barr, S. D.; Leipzig, J.; Shinn, P.; Ecker, J. R.; Bushman, F. D. Integration targeting by avian sarcoma-leukosis virus and human immunodeficiency virus in the chicken genome. J. Virol. 2005. 79, 12035-12044
81. Crise, B.; Li, Y.; Yuan, C.; Morcock, D. R.; Whitby, D.; Munroe, D. J.; Arthur, L. O.; Wu, X. Simian immunodeficiency virus integration preference is similar to that of human immunodeficiency virus type 1. J. Virol. 2005, 79, 12199-12204
82. Doi, K.; Wu, X.; Taniguchi, Y.; Yasunaga, J.; Satou, Y.; Okayama, A.; Nosaka, K.; Matsuoka, M. Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states. Blood 2005, 106, 1048-1053
83. Nowrouzi, A.; Dittrich, M.; Klanke, C.; Heinkelein, M.; Rammling, M.; Dandekar, T.; von Kalle, C.; Rethwilm, A. Genome-wide mapping of foamy virus vector integrations into a human cell line. J. Gen. Virol. 2006, 87, 1339-1347
84. Lewinski, M. K.; Yamashita, M.; Emerman, M.; Ciuffi, A.; Marshall, H.; Crawford, G.; Collins, F.; Shinn, P.; Leipzig, J.; Hannenhalli, S.; Berry, C. C.; Ecker, J. R.; Bushman, F. D. Retroviral DNA integration: Viral and cellular determinants of target-site selection. PLoS Pathog. 2006. 2, e60
85. Barr, S. D.; Ciuffi, A.; Leipzig, J.; Shinn, P.; Ecker, J. R.; Bushman, F. D. HIV integration site selection: Targeting in macrophages and the effects of different routes of viral entry. Mol. Ther. 2006. 14, 218-225
86. Ciuffi, A.; Mitchell, R. S.; Hoffmann, C.; Leipzig, J.; Shinn, P.; Ecker, J. R.; Bushman, F. D. Integration site selection by HIV-based vectors in dividing and growth-arrested IMR-90 lung fibroblasts. Mol. Ther. 2006. 13, 366-373
87. Trobridge, G. D.; Miller, D. G.; Jacobs, M. A.; Allen, J. M.; Kiem, H. P.; Kaul, R.; Russell, D. W. Foamy virus vector integration sites in normal human cells. Proc. Natl. Acad. Sci. USA 2006, 103, 1498-1503
88. Hacker, C. V.; Vink, C. A.; Wardell, T. W.; Lee, S.; Treasure, P.; Kingsman, S. M.; Mitrophanous, K. A.; Miskin, J. E. The integration profile of EIAV-based vectors. Mol. Ther. 2006, 14, 536-545
89. Kim, S.; Kim, Y.; Liang, T.; Sinsheimer, J. S.; Chow, S. A. A high-throughput method for cloning and sequencing human immunodeficiency virus type 1 integration sites. J. Virol. 2006, 80, 11313-11321
90. Levine, B. L.; Humeau, L. M.; Boyer, J.; MacGregor, R. R.; Rebello, T.; Lu, X.; Binder, G. K.; Slepushkin, V.; Lemiale, F.; Mascola, J. R.; Bushman, F. D.; Dropulic, B.; June, C. H. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA 2006, 103, 17372-17377
91. MacNeil, A.; Sankale, J. L.; Meloni, S. T.; Sarr, A. D.; Mboup, S.; Kanki, P. Genomic sites of human immunodeficiency virus type 2 (HIV-2) integration: similarities to HIV-1 in vitro and possible differences in vivo. J. Virol. 2006, 80, 7316-7321
92. Aker, M.; Tubb, J.; Miller, D. G.; Stamatoyannopoulos, G.; Emery, D. W. Integration bias of gammaretrovirus vectors following transduction and growth of primary mouse hematopoietic progenitor cells with and without selection. Mol. Ther. 2006, 14, 226-235
93. Moalic, Y.; Blanchard, Y.; Felix, H.; Jestin, A. Porcine endogenous retrovirus integration sites in the human genome: Features in common with those of murine leukemia virus. J. Virol. 2006, 80, 10980-10988
94. Ikeda, T.; Shibata, J.; Yoshimura, K.; Koito, A.; Matsushita, S. Recurrent HIV-1 integration at the BACH2 locus in resting CD4{thorn} T cell populations during effective highly active antiretroviral therapy. J. Infect. Dis. 2007, 195, 716-725
95. Wang, G. P.; Ciuffi, A.; Leipzig, J.; Berry, C. C.; Bushman, F. D. HIV integration site selection: Analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 2007. 17, 1186-1194
96. Derse, D.; Crise, B.; Li, Y.; Princler, G.; Lum, N.; Stewart, C.; McGrath, C. F.; Hughes, S. H.; Munroe, D. J.;Wu, X. Human T-cell leukemia virus type 1 integration target sites in the human genome: Comparison with those of other retroviruses. J. Virol. 2007, 81, 6731-6741
97. Beard, B. C.; Keyser, K. A.; Trobridge, G. D.; Peterson, L. J.; Miller, D. G.; Jacobs, M.; Kaul, R.; Kiem, H. P. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Hum. Gene. Ther. 2007, 18, 423-434
98. Beard, B. C.; Dickerson, D.; Beebe, K.; Gooch, C.; Fletcher, J.; Okbinoglu, T.; Miller, D. G.; Jacobs, M. A.; Kaul, R.; Kiem, H. P.; Trobridge, G. D. Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol. Ther. 2007, 15, 1356-1365
99. Shun, M. C.; Raghavendra, N. K.; Vandegraaff, N.; Daigle, J. E.; Hughes, S.; Kellam, P.; Cherepanov, P.; Engelman, A. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev. 2007, 21, 1767-1778
100. Kang, Y.; Moressi, C. J.; Scheetz, T. E.; Xie, L.; Tran, D. T.; Casavant, T. L.; Ak, P.; Benham, C. J.; Davidson, B. L.; McCray, P. B., Jr., Integration site choice of a feline immunodeficiency virus vector. J. Virol. 2006, 80, 8820-8823
101. Marshall, H. M.; Ronen, K.; Berry, C.; Llano, M.; Sutherland, H.; Saenz, D.; Bickmore, W.; Poeschla, E.; Bushman, F. D. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS ONE 2007, 2, e1340
102. Faschinger, A.; Rouault, F.; Sollner, J.; Lukas, A.; Salmons, B.; Gunzburg, W. H.; Indik, S. Mouse mammary tumor virus integration site selection in human and mouse genomes. J. Virol. 2008, 83, 1360-1367
103. Margulies, M.; Egholm, M.; Altman,W. E.; Attiya, S.; Bader, J. S.; Bemben, L. A.; Berka, J.; Braverman, M. S.; Chen, Y. J.; Chen, Z.; Dewell, S. B.; Du, L.; Fierro, J. M.; Gomes, X. V.; Godwin, B. C.; He, W.; Helgesen, S.; Ho, C. H.; Irzyk, G. P.; Jando, S. C.; Alenquer,M. L.; Jarvie, T. P.; Jirage, K. B.; Kim, J. B.; Knight, J. R.; Lanza, J. R.; Leamon, J. H.; Lefkowitz, S. M.; Lei, M.; Li, J.; Lohman, K. L.; Lu, H.; Makhijani, V. B.; McDade, K. E.; McKenna, M. P.; Myers, E.W.; Nickerson, E.; Nobile, J. R.; Plant, R.; Puc, B. P.; Ronan, M. T.; Roth, G. T.; Sarkis, G. J.; Simons, J. F.; Simpson, J. W.; Srinivasan, M.; Tartaro, K. R.; Tomasz, A.;Vogt, K. A.;Volkmer,G. A.;Wang, S. H.;Wang, Y.;Weiner,M. P.; Yu, P.; Begley, R. F.; Rothberg, J. M. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005, 437, 376-380
104. Consortium, T. E. P. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science 2004, 306, 636-640
105. Consortium, T. E. P. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007, 447, 799-816
106. Segal, E.; Fondufe-Mittendorf, Y.; Chen, L.; Thastrom, A.; Field, Y.; Moore, I. K.;Wang, J. P.;Widom, J. A genomic code for nucleosome positioning. Nature 2006, 442, 772-778
107. Vijaya, S.; Steffen, D. L.; Robinson, H. L. Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin. J. Virol. 1986, 60, 683-692
108. Rohdewohld, H.;Weiher, H.; Reik,W.; Jaenisch, R.; Breindl, M. Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites. J. Virol. 1987, 61, 336-343
109. Crawford, G. E.; Holt, I. E.; Whittle, J.;Webb, B. D.; Tai, D.; Davis, S.; Margulies, E. H.; Chen, Y.; Bernat, J. A.; Ginsburg, D.; Zhou, D.; Luo, S.; Vasicek, T. J.; Daly, M. J.; Wolfsberg, T. G.; Collins, F. S. Genome-wide mapping of DNase hypersensitive sites using massively parallel signature sequencing (MPSS). Genome Res. 2006, 16, 123-131
110. Roe, T.; Reynolds, T. C.; Yu, G.; Brown, P. O. Integration of murine leukemia virus DNA depends on mitosis. EMBO J 1993, 12, 2099-2108
111. Maertens, G.; Cherepanov, P.; Pluymers, W.; Busschots, K.; De Clercq, E.; Debyser, Z.; Engelborghs, Y. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J. Biol. Chem. 2003, 278, 33528-33539
112. Cherepanov, P.; Devroe, E.; Silver, P. A.; Engelman, A. Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J. Biol. Chem. 2004, 279, 48883-48892
113. Maertens, G.; Cherepanov, P.; Debyser, Z.; Engelborghs, Y.; Engelman, A. Identification and characterization of a functional nuclear localization signal in the HIV-1 integrase interactor LEDGF/p75. J. Biol. Chem. 2004, 279, 33421-33429
114. Llano, M.; Delgado, S.; Vanegas, M.; Poeschla, E. M. Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase. J. Biol. Chem. 2004, 279, 55570-55577
115. Llano, M.; Vanegas, M.; Fregoso, O.; Saenz, D.; Chung, S.; Peretz, M.; Poeschla, E. M. LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes. J. Virol. 2004, 78, 9524-9537
116. Cherepanov, P.; Ambrosio, A. L.; Rahman, S.; Ellenberger, T.; Engelman, A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl. Acad. Sci. USA 2005, 102, 17308-17313
117. Cherepanov, P.; Sun, Z. Y.; Rahman, S.; Maertens, G.; Wagner, G.; Engelman, A. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat. Struct. Mol. Biol. 2005, 12, 526-532
118. Vanegas,M.; Llano, M.; Delgado, S.; Thompson, D.; Peretz, M.; Poeschla, E. Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLSindependent chromatin tethering. J. Cell. Sci. 2005, 118, 1733-1743
119. Busschots, K.; Vercammen, J.; Emiliani, S.; Benarous, R.; Engelborghs, Y.; Christ, F.; Debyser, Z. The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding. J. Biol. Chem. 2005, 280, 17841-17847
120. Emiliani, S.; Mousnier, A.; Busschots, K.; Maroun, M.; Van Maele, B.; Tempe, D.; Vandekerckhove, L.; Moisant, F.; Ben-Slama, L.; Witvrouw, M.; Christ, F.; Rain, J. C.; Dargemont, C.; Debyser, Z.; Benarous, R. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J. Biol. Chem. 2005, 280, 25517-25523
121. Turlure, F.; Maertens, G.; Rahman, S.; Cherepanov, P.; Engelman, A. A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo. Nucleic Acids Res. 2006, 34, 1653-1675
122. Vandekerckhove, L.; Christ, F.; Van Maele, B.; De Rijck, J.; Gijsbers, R.; Van den Haute, C.; Witvrouw, M.; Debyser, Z. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J. Virol. 2006, 80, 1886-1896
123. Llano, M.; Saenz, D. T.; Meehan, A.; Wongthida, P.; Peretz, M.;Walker,W. H.; Teo,W.; Poeschla, E. M. An essential role for LEDGF/p75 in HIV integration. Science 2006, 314, 461-464
124. Llano, M.;Vanegas, M.;Hutchins, N.;Thompson, D.; Delgado, S.; Poeschla, E. M. Identification and characterization of the chromatin-binding domains of the HIV-1 integrase interactor LEDGF/p75. J. Mol. Biol. 2006, 360, 760-773
125. De Rijck, J.; Vandekerckhove, L.; Gijsbers, R.; Hombrouck, A.; Hendrix, J.; Vercammen, J.; Engelborghs, Y.; Christ, F.; Debyser, Z. Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J. Virol. 2006, 80, 11498-11509
126. Busschots, K.; Voet, A.; De Maeyer, M.; Rain, J. C.; Emiliani, S.; Benarous, R.; Desender, L.; Debyser, Z.; Christ, F. Identification of the LEDGF/p75 binding site in HIV-1 integrase. J. Mol. Biol. 2007, 365, 1480-1492
127. Cherepanov, P. LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro. Nucleic Acids Res. 2007, 35, 113-124
128. Violot, S.; Hong, S. S.; Rakotobe, D.; Petit, C.; Gay, B.; Moreau, K.; Billaud, G.; Priet, S.; Sire, J.; Schwartz, O.; Mouscadet, J. F.; Boulanger, P. The human polycomb group EED protein interacts with the integrase of human immunodeficiency virus type 1. J. Virol. 2003, 77, 12507-12522
129. Kalpana, G. V.; Marmon, S.; Wang, W.; Crabtree, G. R.; Goff, S. P. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 1994, 266, 2002-2006
130. Cereseto, A.; Manganaro, L.; Gutierrez, M. I.; Terreni, M.; Fittipaldi, A.; Lusic, M.; Marcello, A.; Giacca, M. Acetylationof HIV-1 integrase by p300 regulates viral integration.EMBOJ 2005, 24, 3070-3081
131. Topper, M.; Luo, Y.; Zhadina, M.; Mohammed, K.; Smith, L.; Muesing, M. A. Posttranslational acetylation of the human immunodeficiency virus type 1 integrase carboxyl-terminal domain is dispensable for viral replication. J. Virol. 2007, 81, 3012-3017
132. Maertens, G.; Vercammen, J.; Debyser, Z.; Engelborghs, Y. Measuring protein-protein interactions inside living cells using single color fluorescence correlation spectroscopy. Application to human immunodeficiency virus type 1 integrase and LEDGF/p75. FASEB J. 2005, 19, 1039-1041
133. Maertens, G.N.; Cherepanov,P.; Engelman,A. Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J. Cell. Sci. 2006, 119, 2563-2571
134. Hombrouck, A.; De Rijck, J.; Hendrix, J.; Vandekerckhove, L.; Voet, A.; De Maeyer, M.;Witvrouw, M.; Engelborghs, Y.; Christ, F.; Gijsbers, R.; Debyser, Z. Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog. 2007, 3, e47
135. Hayouka, Z.; Rosenbluh, J.; Levin, A.; Loya, S.; Lebendiker, M.; Veprintsev, D.; Kotler, M.; Hizi, A.; Loyter, A.; Friedler, A. Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc. Natl. Acad. Sci. USA 2007, 104, 8316-8321
136. Pandey, K. K.; Sinha, S.; Grandgenett, D. P. Transcriptional coactivator LEDGF/p75 modulates human immunodeficiency virus type 1 integrase-mediated concerted integration. J. Virol. 2007, 81, 3969-3979
137. Raghavendra, N. K.; Engelman, A. LEDGF/p75 interferes with the formation of synaptic nucleoprotein complexes that catalyze full-site HIV-1 DNA integration in vitro: Implications for the mechanism of viral cDNA integration. Virology 2007, 360, 1-5
138. Rahman, S.; Lu, R.; Vandegraaff, N.; Cherepanov, P.; Engelman, A. Structure-based mutagenesis of the integrase-LEDGF/ p75 interface uncouples a strict correlation between in vitro protein binding and HIV-1 fitness. Virology 2007, 357, 79-90
139. Yu, F.; Jones, G. S.; Hung, M.; Wagner, A. H.; MacArthur, H. L.; Liu, X.; Leavitt, S.; McDermott, M. J.; Tsiang, M. HIV-1 integrase preassembled on donor DNA is refractory to activity stimulation by LEDGF/p75. Biochemistry 2007, 46, 2899-2908
140. Zielske, S. P.; Stevenson, M. Modest but reproducible inhibition of human immunodeficiency virus type 1 infection in macrophages following LEDGFp75 silencing. J. Virol. 2006, 80, 7275-7280
141. Molteni, V.; Greenwald, J.; Rhodes, D.; Hwang, Y.; Kwiatkowski, W.; Bushman, F. D.; Siegel, J. S.; Choe, S. Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain. Acta Crystallogr. D. Biol. Crystallogr. 2001, 57, 536-544
142. Al-Mawsawi, L. Q.; Fikkert, V.; Dayam, R.; Witvrouw, M.; Burke, T. R., Jr.; Borchers, C. H.; Neamati, N. Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. Proc. Natl. Acad. Sci. USA 2006, 103, 10080-10085
143. Al-Mawsawi, L. Q.; Christ, F.; Dayam, R.; Debyser, Z.; Neamati, N. Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: Insight into integrase-DNA complex formation and catalysis. FEBS Lett. 2008, 582, 1425-1430
144. Bushman, F. D. Retroviral integration and human gene therapy. J. Clin. Invest. 2007, 117, 2083-2086
145. Pike-Overzet, K.; van der Burg, M.; Wagemaker, G.; van Dongen, J. J.; Staal, F. J. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol. Ther. 2007, 15, 1910-1916
146. Cavazzana-Calvo, M.; Fischer, A. Gene therapy for severe combined immunodeficiency: Are we there yet? J. Clin. Invest. 2007, 117, 1456-1465
147. Kimmelman, J. The ethics of human gene transfer. Nat. Rev. Genet. 2008, 9, 239-244
148. Cavazzana-Calvo, M.; Hacein-Bey, S.; de Saint Basile, G.; Gross, F.; Yvon, E.; Nusbaum, P.; Selz, F.; Hue, C.; Certain, S.; Casanova, J. L.; Bousso, P.; Deist, F. L.; Fischer, A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288, 669-672
149. Cavazzana-Calvo, M.; Lagresle, C.; Hacein-Bey-Abina, S.; Fischer, A. Gene therapy for severe combined immunodeficiency. Annu. Rev. Med. 2005, 56, 585-602
150. Gaspar, H. B.; Parsley, K. L.; Howe, S.; King, D.; Gilmour, K. C.; Sinclair, J.; Brouns, G.; Schmidt, M.; Von Kalle, C.; Barington, T.; Jakobsen, M. A.; Christensen, H. O.; Al Ghonaium, A.; White, H. N.; Smith, J. L.; Levinsky, R. J.; Ali, R. R.; Kinnon, C.; Thrasher, A. J. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004. 364, 2181-2187
151. Schwarzwaelder, K.; Howe, S. J.; Schmidt, M.; Brugman, M. H.; Deichmann, A.; Glimm, H.; Schmidt, S.; Prinz, C.; Wissler, M.; King, D. J.; Zhang, F.; Parsley, K. L.; Gilmour, K. C.; Sinclair, J.; Bayford, J.; Peraj, R.; Pike-Overzet, K.; Staal, F. J.; de Ridder, D.; Kinnon, C.; Abel, U.; Wagemaker, G.; Gaspar, H. B.; Thrasher, A. J.; von Kalle, C. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J. Clin. Invest. 2007, 117, 2241-2249
152. Aiuti, A.; Slavin, S.; Aker, M.; Ficara, F.; Deola, S.; Mortellaro, A.; Morecki, S.; Andolfi, G.; Tabucchi, A.; Carlucci, F.; Marinello, E.; Cattaneo, F.; Vai, S.; Servida, P.; Miniero, R.; Roncarolo, M. G.; Bordignon, C. Correction of ADASCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002, 296, 2410-2413
153. Ott, M. G.; Schmidt, M.; Schwarzwaelder, K.; Stein, S.; Siler, U.; Koehl, U.; Glimm, H.; Kuhlcke, K.; Schilz, A.; Kunkel, H.; Naundorf, S.; Brinkmann, A.; Deichmann, A.; Fischer, M.; Ball, C.; Pilz, I.; Dunbar, C.; Du, Y.; Jenkins, N. A.; Copeland, N. G.; Luthi, U.; Hassan, M.; Thrasher, A. J.; Hoelzer, D.; von Kalle, C.; Seger, R.; Grez, M. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 2006, 12, 401-409
154. Gaspar, H. B.; Bjorkegren, E.; Parsley, K.; Gilmour, K. C.; King, D.; Sinclair, J.; Zhang, F.; Giannakopoulos, A.; Adams, S.; Fairbanks, L. D.; Gaspar, J.; Henderson, L.; Xu-Bayford, J. H.; Davies, E. G.; Veys, P. A.; Kinnon, C.; Thrasher, A. J. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol. Ther. 2006, 14, 505-513
155. Hacein-Bey-Abina, S.; de Saint Basile, G.; Cavazzana-Calvo, M. Gene therapy of X-linked severe combined immunodeficiency. Methods Mol. Biol. 2003, 215, 247-259
156. Hacein-Bey-Abina, S.; von Kalle, C.; Schmidt, M.; Le Deist, F.; Wulffraat, N.; McIntyre, E.; Radford, I.; Villeval, J. L.; Fraser, C. C.; Cavazzana-Calvo, M.; Fischer, A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003, 348, 255-256
157. Deichmann, A.; Hacein-Bey-Abina, S.; Schmidt, M.; Garrigue, A.; Brugman, M. H.; Hu, J.; Glimm, H.; Gyapay, G.; Prum, B.; Fraser, C. C.; Fischer, N.; Schwarzwaelder, K.; Siegler, M. L.; de Ridder, D.; Pike-Overzet, K.; Howe, S. J.; Thrasher, A. J.; Wagemaker, G.; Abel, U.; Staal, F. J.; Delabesse, E.; Villeval, J. L.; Aronow, B.; Hue, C.; Prinz, C.; Wissler, M.; Klanke, C.; Weissenbach, J.; Alexander, I.; Fischer, A.; von Kalle, C.; Cavazzana-Calvo, M. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 2007, 117, 2225-2232
158. Yu, S. F.; von Ruden, T.; Kantoff, P. W.; Garber, C.; Seiberg, M.; Ruther, U.; Anderson, W. F.; Wagner, E. F.; Gilboa, E. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA 1986, 83, 3194-3198
159. Naldini, L.; Blomer, U.; Gallay, P.; Ory, D.; Mulligan, R.; Gage, F. H.; Verma, I. M.; Trono, D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272, 263-267
160. Dull, T.; Zufferey, R.; Kelly, M.; Mandel, R. J.; Nguyen, M.; Trono, D.; Naldini, L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 1998, 72, 8463-8471
161. Miyoshi, H.; Blomer, U.; Takahashi, M.; Gage, F. H.; Verma, I. M. Development of a self-inactivating lentivirus vector. J. Virol. 1998, 72, 8150-8157
162. Zufferey, R.; Donello, J. E.; Trono, D.; Hope, T. J. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 1999, 73, 2886-2892
163. Zaiss, A. K.; Son, S.; Chang, L. J. RNA 30 readthrough of oncoretrovirus and lentivirus: Implications for vector safety and efficacy. J. Virol. 2002, 76, 7209-7219
164. Yi, Y.; Hahm, S. H.; Lee, K. H. Retroviral gene therapy: Safety issues and possible solutions. Curr. Gene. Ther. 2005, 5, 25-35
165. Baum, C.; Schambach, A.; Bohne, J.; Galla, M. Retrovirus vectors: Toward the plentivirus? Mol. Ther. 2006, 13, 1050-1063
166. Weber, E. L.; Cannon, P. M. Promoter choice for retroviral vectors: Transcriptional strength versus trans-activation potential. Hum. Gene. Ther. 2007, 18, 849-860
167. Schambach, A.; Galla, M.; Maetzig, T.; Loew, R.; Baum, C. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol. Ther. 2007, 15, 1167-1173
168. Higashimoto, T.; Urbinati, F.; Perumbeti, A.; Jiang, G.; Zarzuela, A.; Chang, L. J.; Kohn, D. B.; Malik, P. The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther. 2007, 14, 1298-1304
169. Arumugam, P. I.; Scholes, J.; Perelman, N.; Xia, P.; Yee, J. K.; Malik, P. Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol. Ther. 2007, 15, 1863-1871
170. Zychlinski, D.; Schambach, A.; Modlich, U.; Maetzig, T.; Meyer, J.; Grassman, E.; Mishra, A.; Baum, C. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 2008, 16, 718-725
171. Hendrie,P. C.;Huo,Y.; Stolitenko, R. B.; Russell,D.W. Arapid and quantitative assay for measuring neighboring gene activation by vector proviruses. Mol. Ther. 2008, 16, 534-540.